Ivermectin as a Novel Therapy in COVID-19 Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04403555 |
Recruitment Status :
Recruiting
First Posted : May 27, 2020
Last Update Posted : January 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID | Drug: Ivermectin | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 160 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Efficacy of Ivermectin in COVID-19 Treatment |
Actual Study Start Date : | June 1, 2020 |
Estimated Primary Completion Date : | December 1, 2030 |
Estimated Study Completion Date : | December 3, 2030 |

Arm | Intervention/treatment |
---|---|
Experimental: Ivermectin
Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
|
Drug: Ivermectin
Ivermectin treatment
Other Name: iverzine, ivermectin |
No Intervention: Standard of care
Standard of care treatment
|
- The number of patients with improvement or mortality [ Time Frame: 1 month ]The number of patients with improvement or mortality

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- COVID 19 positive patients
Exclusion Criteria:
- Allergy or contraindication to the drug

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04403555
Contact: Sherief Abd-Elsalam, ass. prof. | 00201147773440 | sheriefabdelsalam@yahoo.com |
Egypt | |
Sherief Abd-Elsalam | Recruiting |
Tanta, Egypt | |
Contact: Sherief Abd-Elsalam, Ass. Prof. 00201009221243 sheriefabdelsalam@yahoo.com |
Principal Investigator: | sherief Abd-Elsalam, Ass. Prof. | ass. Prof. Tropical Medicine |
Responsible Party: | Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University |
ClinicalTrials.gov Identifier: | NCT04403555 |
Other Study ID Numbers: |
tanta covid treatment |
First Posted: | May 27, 2020 Key Record Dates |
Last Update Posted: | January 20, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ivermectin Antiparasitic Agents Anti-Infective Agents |